MedPacto Inc
KOSDAQ:235980
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
MedPacto Inc
Cash from Financing Activities
MedPacto Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MedPacto Inc
KOSDAQ:235980
|
Cash from Financing Activities
-₩635.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-60%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cash from Financing Activities
₩339.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Cash from Financing Activities
₩123.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Cash from Financing Activities
₩3.9B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash from Financing Activities
₩155.6B
|
CAGR 3-Years
276%
|
CAGR 5-Years
15%
|
CAGR 10-Years
103%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash from Financing Activities
₩32.5B
|
CAGR 3-Years
91%
|
CAGR 5-Years
122%
|
CAGR 10-Years
N/A
|
|
MedPacto Inc
Glance View
MedPacto, Inc. researches and develops anti-cancer drugs. The company is headquartered in Seoul, Seoul. The company went IPO on 2019-12-19. The firm researches and develops anticancer drugs and diagnostic kits including vactosertib, MA-B2 and others. The products are used as the treatment of multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer and pancreatic cancer, among others.
See Also
What is MedPacto Inc's Cash from Financing Activities?
Cash from Financing Activities
-635.1m
KRW
Based on the financial report for Dec 31, 2025, MedPacto Inc's Cash from Financing Activities amounts to -635.1m KRW.
What is MedPacto Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-60%
Over the last year, the Cash from Financing Activities growth was 25%.
